Protein / target

Sodium/potassium-transporting ATPase subunit gamma

FXYD2P54710Homo sapiensSwiss-Prot
Clinically validated
Therapeutic maturity
5
Approved medicines
30
Clinical trials
Small-molecule tractable
Druggability
Advanced Clinical

Protein at a glance

Biological role

Protein-macromolecule adaptor activity

Strongest disease association

type 2 diabetes mellitus

Genetic evidence · score 0.74

Therapeutic maturity

Clinically validated target

5 approved medicines against this target

Druggability

Small molecule

Open Targets tractability · Advanced Clinical

Clinical development

5 approved · 1 in clinical development

30 linked trials

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function

May be involved in forming the receptor site for cardiac glycoside binding or may modulate the transport function of the sodium ATPase

Subcellular location

Membrane
Domains and Gene Ontology detail (15)

Gene Ontology

  • Cbasolateral plasma membrane
  • Cextracellular exosome
  • Cplasma membrane
  • Csodium:potassium-exchanging ATPase complex
  • FATPase activator activity
  • Fprotein-macromolecule adaptor activity
  • Fsodium channel regulator activity
  • Pcellular hyperosmotic salinity response
  • Pestablishment or maintenance of transmembrane electrochemical gradient
  • Pnegative regulation of cell population proliferation
  • Ppositive regulation of sodium ion export across plasma membrane
  • Ppotassium ion import across plasma membrane

66 aa · 7 kDa · 2 isoforms

Biological roles

Reactome v97

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

View underlying pathways (3)

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Interaction neighbourhood

STRING v12.0

Proteins with the strongest functional or physical association. Node size and line weight reflect STRING confidence; hover or select a partner to inspect one association.

ATP1B1ATP1A4ATP1A3ATP1A1ATP1A2ATP1B2ATP1B3ATP1B4CLDN16FXYD1FXYD2

10 strongest partners — larger node and heavier line mean higher confidence

Functional and physical associations from STRING v12.0. Only associations with this protein are drawn — partner-to-partner links are not part of this evidence.

Drugs targeting this protein

1

Whether each drug engages this protein directly or through a complex, and how many other targets are recorded for it. Direct binders with few recorded targets are listed first.

Digoxin
ApprovedInhibitor

Sodium/potassium-transporting ATPase inhibitor

Appears in clinical studies involving congestive heart failure, atrial fibrillation, heart failure, cardiovascular disorder

Acts on a complex — shared with ATP1A1, ATP1B2, ATP1B1 +4 more · 1 of 8 recorded protein targets — broad pharmacology

ChEMBL mechanism, action type and target identity. Open Targets clinical status and indications.

Translational evidence

Open Targets 26

Why this target matters therapeutically — disease associations, drugs in development, tractability and safety, from Open Targets.

Strongest genetic associations

Human genetic evidence — the most direct causal link between this target and a disease.

type 2 diabetes mellitus0.74

Genetic · overall 0.47

renal hypomagnesemia 20.65

Genetic · overall 0.55

Autosomal dominant primary hypomagnesemia with hypocalciuria0.61

Genetic · overall 0.52

Highest-confidence therapeutic associations

Diseases where a drug acting on this target has already reached clinical development.

congestive heart failure0.99

Clinical · overall 0.60

atrial fibrillation0.98

Clinical · overall 0.60

heart failure0.95

Clinical · overall 0.58

cardiovascular disorder0.91

Clinical · overall 0.55

Arrhythmia0.83

Clinical · overall 0.50

Highest overall evidence

Remaining associations by Open Targets' aggregated evidence score.

neurodegenerative disease0.41

Pathway

Supraventricular tachycardia0.32

Clinical

Show all associations
congestive heart failure0.60
atrial fibrillation0.60
heart failure0.58
renal hypomagnesemia 20.55
cardiovascular disorder0.55
Autosomal dominant primary hypomagnesemia with hypocalciuria0.52
Arrhythmia0.50
type 2 diabetes mellitus0.47
neurodegenerative disease0.41
Supraventricular tachycardia0.32

Open Targets ranks 146 associations for this target and we store the top 10 by aggregated score. The long tail is largely literature co-mention and RNA-expression evidence, not evidence that this target drives those diseases.

Known drugs · 6 total

ISTAROXIMEPhase 2 3

heart disorder · heart failure · heart failure

DIGOXINApproval

congestive heart failure · atrial fibrillation · heart failure

ACETYLDIGITOXINApproval

cardiovascular disorder · congestive heart failure

DESLANOSIDEApproval

cardiovascular disorder · Arrhythmia · heart failure

DIGITOXINApproval

cardiovascular disorder · Arrhythmia · heart failure

LANATOSIDE CApproval

cardiovascular disorder

Tractability

SM · Advanced ClinicalSM · Structure with LigandSM · High-Quality LigandSM · Druggable FamilyAB · GO CC high confAB · UniProt SigP or TMHMM

Clinical trials

30

Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein.

Show remaining trials (24)

RECRUITING · via Digoxin · NCT06588699

ClinicalTrials.gov via the drug-target graph.

Forefront confidence

Synthesis

Our own weighting of the evidence behind each disease association. Human genetics and clinical evidence count for most; literature co-mention counts for little, because two entities sharing an abstract is not evidence that one drives the other.

type 2 diabetes mellitusWell supported
0.77
agreement 0.670.88
Genetic84%Clinical10%Literature5%

Open Targets aggregate 0.47 · 3 independent evidence families

congestive heart failureModerately supported
0.74
agreement 0.570.91
Clinical100%

Open Targets aggregate 0.60 · 1 independent evidence family

atrial fibrillationModerately supported
0.73
agreement 0.580.89
Clinical100%Literature0%

Open Targets aggregate 0.60 · 2 independent evidence families

heart failureModerately supported
0.71
agreement 0.560.87
Clinical99%Literature1%

Open Targets aggregate 0.58 · 2 independent evidence families

cardiovascular disorderModerately supported
0.68
agreement 0.520.84
Clinical100%

Open Targets aggregate 0.55 · 1 independent evidence family

This ranking differs from Open Targets' own: re-weighting moves genetically-evidenced diseases above more heavily co-mentioned ones. The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the underlying per-type scores are shown above so the calculation can be checked.

What's happening now

3

Recent activity around this target, drawn from one canonical event stream. Every item is reached through a drug that targets this protein, so each event is news about that drug rather than about the protein directly.

  1. Trial status changed2026-07-20

    A Phase 1 Study to Evaluate the Effect of Multiple Doses of ABBV-722 on the Pharmacokinetics of Cocktail Probe Substrates of CYP3A and Select Transporters in Healthy Adult Subjects

    Status changed to Active, not recruiting · ClinicalTrials.gov · via Digoxin

  2. New publication2024-01-25
    Drug-Drug Interactions Between Glucagon-Like Peptide 1 Receptor Agonists and Oral Medications: A Systematic Review.

    Drug safety · 2024 · 37 citations · Europe PMC · via Digoxin

  3. New publication2002-12-01
    Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: the Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial.

    JAMA · 2002 · 1,354 citations · Europe PMC · via Digoxin

Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.